{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:03:08Z","timestamp":1782903788821,"version":"3.54.5"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The Infectious Diseases Clinical Research Consortium and Vaccine Treatment Evaluation Units (VTEUs) are a network of clinicians and scientists who work together with the National Institutes of Allergy and Infectious Diseases to advance vaccines and therapeutics to combat infectious diseases. For more than 60 years, the VTEUs have led Phase 1\u20134 clinical trials, with a strong focus on Phase 1\/2 trials, evaluating the safety, reactogenicity, optimal doses, routes of administration, and schedules for vaccines and treatments. Our future goals focus on advancing vaccine science and innovation through clinical and translational studies; achieving equitable representation in clinical trials across the human lifespan to facilitate disease prevention in vulnerable populations; advancing national and global health priorities through collaborations that leverage complementary strengths and foster preparedness and rapid responses; and developing the next generation of clinical and translational researchers through structured mentorship and training opportunities. Our long-term vision is to develop safe and effective vaccines and therapeutics to combat infectious diseases and enhance health and well-being for all.<\/jats:p>","DOI":"10.1093\/cid\/ciaf412","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:22:04Z","timestamp":1760113324000},"page":"S137-S146","source":"Crossref","is-referenced-by-count":2,"title":["Future Goals and Long-term Vision of the Infectious Diseases Clinical Research Consortium\/Vaccine and Treatment Evaluation Unit Network"],"prefix":"10.1093","volume":"81","author":[{"given":"Jennifer A","family":"Whitaker","sequence":"first","affiliation":[{"name":"Departments of Molecular Virology, Microbiology, and Medicine, Baylor College of Medicine , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-063X","authenticated-orcid":false,"given":"Paulina A","family":"Rebolledo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-7432","authenticated-orcid":false,"given":"David","family":"Dobrzynski","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Rochester , Rochester, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie I","family":"Samanovic","sequence":"additional","affiliation":[{"name":"NYU Langone Vaccine Center, Department of Medicine, NYU Grossman School of Medicine , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hoft","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, Division of Infectious Diseases, Allergy & Immunology, Departments of Internal Medicine and Molecular Microbiology & Immunology, Saint Louis University School of Medicine, Saint Louis University , St. Louis, Missouri ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Stephens","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8439-0592","authenticated-orcid":false,"given":"Christina A","family":"Rostad","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2025101012215549100_ciaf412-B1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/aje\/kwac186","article-title":"Exposure, susceptibility, and recovery: a framework for examining the intersection of the social and physical environments and infectious disease risk","volume":"192","author":"Noppert","year":"2023","journal-title":"Am J Epidemiol"},{"key":"2025101012215549100_ciaf412-B2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciaa815","article-title":"The disproportionate impact of COVID-19 on racial and ethnic minorities in the United States","volume":"72","author":"Tai","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025101012215549100_ciaf412-B3","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.15585\/mmwr.mm7240a3","article-title":"COVID-19-associated hospitalizations among U.S. adults aged \u226565 years\u2014COVID-NET, 13 states, January\u2013August 2023","volume":"72","author":"Taylor","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025101012215549100_ciaf412-B4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.15585\/mmwr.mm7111e2","article-title":"Hospitalization of infants and children aged 0\u20134 years with laboratory-confirmed COVID-19\u2014COVID-NET, 14 states, March 2020\u2013February 2022","volume":"71","author":"Marks","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025101012215549100_ciaf412-B5","doi-asserted-by":"crossref","first-page":"E540","DOI":"10.1503\/cmaj.202604","article-title":"The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis","volume":"193","author":"Wei","year":"2021","journal-title":"CMAJ"},{"key":"2025101012215549100_ciaf412-B6","doi-asserted-by":"crossref","first-page":"100747","DOI":"10.1016\/j.lanepe.2023.100747","article-title":"Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study","volume":"35","author":"Evans","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2025101012215549100_ciaf412-B7","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2209367","article-title":"Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age","volume":"387","author":"Anderson","year":"2022","journal-title":"N Engl J Med"},{"key":"2025101012215549100_ciaf412-B8","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa2203315","article-title":"Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age","volume":"386","author":"Creech","year":"2022","journal-title":"N Engl J Med"},{"key":"2025101012215549100_ciaf412-B9","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/infdis\/jis445","article-title":"Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009\u20132010 seasonal trivalent influenza vaccinations","volume":"206","author":"Frey","year":"2012","journal-title":"J Infect Dis"},{"key":"2025101012215549100_ciaf412-B10","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1016\/j.vaccine.2019.07.085","article-title":"Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents","volume":"37","author":"Munoz","year":"2019","journal-title":"Vaccine"},{"key":"2025101012215549100_ciaf412-B11","doi-asserted-by":"crossref","first-page":"e20152603","DOI":"10.1542\/peds.2015-2603","article-title":"Safety and immunogenicity of sequential rotavirus vaccine schedules","volume":"137","author":"Libster","year":"2016","journal-title":"Pediatrics"},{"key":"2025101012215549100_ciaf412-B12","author":"National Institute of Health"},{"key":"2025101012215549100_ciaf412-B13","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1016\/j.vaccine.2020.05.059","article-title":"Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants","volume":"38","author":"Munoz","year":"2020","journal-title":"Vaccine"},{"key":"2025101012215549100_ciaf412-B14","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1001\/jama.2014.3633","article-title":"Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial","volume":"311","author":"Munoz","year":"2014","journal-title":"JAMA"},{"key":"2025101012215549100_ciaf412-B15","doi-asserted-by":"crossref","first-page":"e2023064252","DOI":"10.1542\/peds.2023-064252","article-title":"Maternal COVID-19 vaccination and prevention of symptomatic infection in infants","volume":"153","author":"Cardemil","year":"2024","journal-title":"Pediatrics"},{"key":"2025101012215549100_ciaf412-B16","author":"Fred Hutchinson Cancer Center"},{"key":"2025101012215549100_ciaf412-B17","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1093\/cid\/ciaf377","article-title":"Historical advances in clinical trial design and expanding representation as the new frontier for innovation","volume":"81","author":"Jano","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025101012215549100_ciaf412-B18","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2\u2014preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"2025101012215549100_ciaf412-B19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"2025101012215549100_ciaf412-B20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"key":"2025101012215549100_ciaf412-B21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/infdis\/jiad611","article-title":"Metabolomic signatures differentiate immune responses in avian influenza vaccine recipients","volume":"230","author":"Howard","year":"2024","journal-title":"J Infect Dis"},{"key":"2025101012215549100_ciaf412-B22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.immuni.2010.10.006","article-title":"Systems vaccinology","volume":"33","author":"Pulendran","year":"2010","journal-title":"Immunity"},{"key":"2025101012215549100_ciaf412-B23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"2025101012215549100_ciaf412-B24","doi-asserted-by":"crossref","first-page":"909406","DOI":"10.1155\/2015\/909406","article-title":"Application of \u201csystems vaccinology\u201d to evaluate inflammation and reactogenicity of adjuvanted preventative vaccines","volume":"2015","author":"Lewis","year":"2015","journal-title":"J Immunol Res"},{"key":"2025101012215549100_ciaf412-B25","doi-asserted-by":"crossref","first-page":"eade9078","DOI":"10.1126\/scitranslmed.ade9078","article-title":"Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial","volume":"15","author":"Benkeser","year":"2023","journal-title":"Sci Transl Med"},{"key":"2025101012215549100_ciaf412-B26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41541-023-00630-0","article-title":"Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine","volume":"8","author":"Benkeser","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2025101012215549100_ciaf412-B27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41467-022-35768-3","article-title":"Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial","volume":"14","author":"Fong","year":"2023","journal-title":"Nat Commun"},{"key":"2025101012215549100_ciaf412-B28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"2025101012215549100_ciaf412-B29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41541-024-01042-4","article-title":"A phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose","volume":"9","author":"Rostad","year":"2024","journal-title":"NPJ Vaccines"},{"key":"2025101012215549100_ciaf412-B30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.immuni.2022.01.001","article-title":"mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern","volume":"55","author":"Kaplonek","year":"2022","journal-title":"Immunity"},{"key":"2025101012215549100_ciaf412-B31","doi-asserted-by":"crossref","first-page":"eadi8039","DOI":"10.1126\/sciimmunol.adi8039","article-title":"AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans","volume":"9","author":"Grigoryan","year":"2024","journal-title":"Sci Immunol"},{"key":"2025101012215549100_ciaf412-B32","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.4049\/jimmunol.2001420","article-title":"Evaluation of cellular and serological responses to acute SARS-CoV-2 infection demonstrates the functional importance of the receptor-binding domain","volume":"206","author":"Mantus","year":"2021","journal-title":"J Immunol"},{"key":"2025101012215549100_ciaf412-B33","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.immuni.2023.06.018","article-title":"Innate immunity and interferon in SARS-CoV-2 infection outcome","volume":"56","author":"Savan","year":"2023","journal-title":"Immunity"},{"key":"2025101012215549100_ciaf412-B34","doi-asserted-by":"crossref","first-page":"jiaf176","DOI":"10.1093\/infdis\/jiaf176","article-title":"Mucosal and systemic antibody responses after boosting with a bivalent messenger RNA severe acute respiratory syndrome coronavirus 2 vaccine","author":"Atmar","year":"2025","journal-title":"J Infect Dis"},{"key":"2025101012215549100_ciaf412-B35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1084\/jem.20151960","article-title":"Reverse vaccinology 2.0: human immunology instructs vaccine antigen design","volume":"213","author":"Rappuoli","year":"2016","journal-title":"J Exp Med"},{"key":"2025101012215549100_ciaf412-B36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41586-021-04356-8","article-title":"Broadly neutralizing antibodies target a haemagglutinin anchor epitope","volume":"602","author":"Guthmiller","year":"2022","journal-title":"Nature"},{"key":"2025101012215549100_ciaf412-B37","doi-asserted-by":"crossref","first-page":"105785","DOI":"10.1016\/j.antiviral.2023.105785","article-title":"Broadly neutralizing antibodies to combat influenza virus infection","volume":"221","author":"Sun","year":"2024","journal-title":"Antiviral Res"},{"key":"2025101012215549100_ciaf412-B38","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"2025101012215549100_ciaf412-B39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","article-title":"Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses","volume":"23","author":"Chen","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2025101012215549100_ciaf412-B40","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1016\/j.vaccine.2019.07.033","article-title":"Highly conserved influenza T cell epitopes induce broadly protective immunity","volume":"37","author":"Eickhoff","year":"2019","journal-title":"Vaccine"},{"key":"2025101012215549100_ciaf412-B41","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"2025101012215549100_ciaf412-B42","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/cid\/ciae173","article-title":"A phase 2 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of different prime-boost vaccination schedules of 2013 and 2017 A(H7N9) inactivated influenza virus vaccines administered with and without AS03 adjuvant in healthy US adults","volume":"78","author":"Rostad","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025101012215549100_ciaf412-B43","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/infdis\/jiad276","article-title":"Safety and immunogenicity of a delayed heterologous avian influenza A(H7N9) vaccine boost following different priming regimens: a randomized clinical trial","volume":"229","author":"El Sahly","year":"2024","journal-title":"J Infect Dis"},{"key":"2025101012215549100_ciaf412-B44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41541-023-00693-z","article-title":"Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants","volume":"8","author":"Lyke","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2025101012215549100_ciaf412-B45","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2025101012215549100_ciaf412-B46","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2025101012215549100_ciaf412-B47","doi-asserted-by":"crossref","first-page":"1043109","DOI":"10.3389\/fimmu.2023.1043109","article-title":"New-age vaccine adjuvants, their development, and future perspective","volume":"14","author":"Verma","year":"2023","journal-title":"Front Immunol"},{"key":"2025101012215549100_ciaf412-B48","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.vaccine.2023.12.001","article-title":"Immunogenicity and safety of varying dosages of a fifth-wave influenza A\/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults","volume":"42","author":"Jackson","year":"2024","journal-title":"Vaccine"},{"key":"2025101012215549100_ciaf412-B49","doi-asserted-by":"crossref","first-page":"126702","DOI":"10.1016\/j.vaccine.2024.126702","article-title":"Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59(R)","volume":"47","author":"Frey","year":"2025","journal-title":"Vaccine"},{"key":"2025101012215549100_ciaf412-B50","doi-asserted-by":"crossref","first-page":"ciac983","DOI":"10.1093\/cid\/ciac983","article-title":"Safety and immunogenicity of a monovalent inactivated influenza A\/H5N8 virus vaccine given with and without AS03 or MF59 adjuvants in healthy adults","author":"Winokur","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025101012215549100_ciaf412-B51","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/infdis\/jiab206","article-title":"Topical imiquimod does not provide an adjuvant effect when administered with inactivated influenza A\/H5N1 vaccine in healthy young adults","volume":"224","author":"El Sahly","year":"2021","journal-title":"J Infect Dis"},{"key":"2025101012215549100_ciaf412-B52","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.vaccine.2020.11.051","article-title":"Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older","volume":"39","author":"Winokur","year":"2021","journal-title":"Vaccine"},{"key":"2025101012215549100_ciaf412-B53","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines\u2014fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2025101012215549100_ciaf412-B54","author":"National Library of Medicine"},{"key":"2025101012215549100_ciaf412-B55","doi-asserted-by":"crossref","first-page":"e073747","DOI":"10.1136\/bmj-2022-073747","article-title":"US public investment in development of mRNA covid-19 vaccines: retrospective cohort study","volume":"380","author":"Lalani","year":"2023","journal-title":"BMJ"},{"key":"2025101012215549100_ciaf412-B56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/d41586-023-03289-8","article-title":"Scientists deliberately gave women Zika\u2014here's why","volume":"623","author":"Lenharo","year":"2023","journal-title":"Nature"},{"key":"2025101012215549100_ciaf412-B57","doi-asserted-by":"crossref","first-page":"e70014","DOI":"10.1111\/irv.70014","article-title":"Inno4Vac Workshop report part 1: controlled human influenza virus infection model (CHIVIM) strain selection and immune assays for CHIVIM studies, November 2021, MHRA, UK","volume":"18","author":"Waldock","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"2025101012215549100_ciaf412-B58","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.vaccine.2014.10.083","article-title":"Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009\u20132010 seasonal trivalent influenza vaccinations","volume":"33","author":"Frey","year":"2015","journal-title":"Vaccine"},{"key":"2025101012215549100_ciaf412-B59","doi-asserted-by":"crossref","first-page":"ofu102","DOI":"10.1093\/ofid\/ofu102","article-title":"Point-of-use mixing of influenza H5N1 vaccine and MF59 adjuvant for pandemic vaccination preparedness: antibody responses and safety. A phase 1 clinical trial","volume":"1","author":"Mulligan","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"2025101012215549100_ciaf412-B60","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"key":"2025101012215549100_ciaf412-B61","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1016\/j.vaccine.2019.04.066","article-title":"Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A\/H5N1 vaccines: a meta-analysis","volume":"37","author":"Keitel","year":"2019","journal-title":"Vaccine"},{"key":"2025101012215549100_ciaf412-B62","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.vaccine.2019.03.071","article-title":"Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A\/H7N7-H7N9 vaccination","volume":"37","author":"El Sahly","year":"2019","journal-title":"Vaccine"},{"key":"2025101012215549100_ciaf412-B63","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"key":"2025101012215549100_ciaf412-B64","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N Engl J Med"},{"key":"2025101012215549100_ciaf412-B65","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1086\/374564","article-title":"Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax","volume":"187","author":"Newman","year":"2003","journal-title":"J Infect Dis"},{"key":"2025101012215549100_ciaf412-B66","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa020534","article-title":"Clinical responses to undiluted and diluted smallpox vaccine","volume":"346","author":"Frey","year":"2002","journal-title":"N Engl J Med"},{"key":"2025101012215549100_ciaf412-B67","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jama.292.10.1205","article-title":"Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial","volume":"292","author":"Talbot","year":"2004","journal-title":"JAMA"},{"key":"2025101012215549100_ciaf412-B68","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1016\/j.vaccine.2015.06.075","article-title":"Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naive subjects","volume":"33","author":"Frey","year":"2015","journal-title":"Vaccine"},{"key":"2025101012215549100_ciaf412-B69","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1016\/j.vaccine.2014.08.076","article-title":"Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults","volume":"32","author":"Bernstein","year":"2014","journal-title":"Vaccine"},{"key":"2025101012215549100_ciaf412-B70","doi-asserted-by":"crossref","first-page":"e0010480","DOI":"10.1371\/journal.pntd.0010480","article-title":"Challenges and lessons learned from the rapid operationalization of a prospective cohort to study the natural history and neurodevelopmental outcomes of postnatal Zika virus infection among infants and children in rural Guatemala","volume":"16","author":"Paniagua-Avila","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2025101012215549100_ciaf412-B71","doi-asserted-by":"crossref","first-page":"1247876","DOI":"10.3389\/fimmu.2023.1247876","article-title":"Identification of immunodominant T cell epitopes induced by natural Zika virus infection","volume":"14","author":"Eickhoff","year":"2023","journal-title":"Front Immunol"},{"key":"2025101012215549100_ciaf412-B72","doi-asserted-by":"crossref","first-page":"ofy352","DOI":"10.1093\/ofid\/ofy352","article-title":"Clinical, virologic, and immunologic characteristics of Zika virus infection in a cohort of US patients: prolonged RNA detection in whole blood","volume":"6","author":"El Sahly","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025101012215549100_ciaf412-B73","author":"National Library of Medicine"},{"key":"2025101012215549100_ciaf412-B74","author":"National Library of Medicine"},{"key":"2025101012215549100_ciaf412-B75","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1093\/cid\/ciaf419","article-title":"Baptism in a pandemic: Infectious Diseases Clinical Research Consortium (IDCRC) Network design for readiness and response","volume":"81","author":"Dionne","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025101012215549100_ciaf412-B76","author":"National Institutes of Health"},{"key":"2025101012215549100_ciaf412-B77","author":"National Library of Medicine"},{"key":"2025101012215549100_ciaf412-B78","author":"National Library of Medicine"},{"key":"2025101012215549100_ciaf412-B79","author":"National Library of Medicine"},{"key":"2025101012215549100_ciaf412-B80","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1093\/cid\/ciaf378","article-title":"Innovations in career development through mentoring in the VTEU\/IDCRC programs","volume":"81","author":"Danzinger-Isakov","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025101012215549100_ciaf412-B81","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/cid\/ciz529","article-title":"Improving the infectious diseases physician scientist workforce from the view of junior investigators: vision, transparency, and reproducibility","volume":"70","author":"Collins","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/Supplement_2\/S137\/64613675\/ciaf412.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/Supplement_2\/S137\/64613675\/ciaf412.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:22:11Z","timestamp":1760113331000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/Supplement_2\/S137\/8280514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":81,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2025,10,10]]},"published-print":{"date-parts":[[2025,10,10]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf412","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,15]]},"published":{"date-parts":[[2025,10,10]]}}}